Placenta growth factor expression is correlated with survival of patients with colorectal cancer

WeI, S.-C.; Tsoo, P.-N.; Yu, S.-C.; Shun, C.-T.; Tsai-Wu, J.-J.; Wu, C. H. H.; Su, Y.-N.; Hsieh, F.-J.; Wong, J.-M.
May 2005
Gut;May2005, Vol. 54 Issue 5, p666
Academic Journal
Background: Overexpression of vascular endothelial growth factor (VEGF) correlates with vascularity, metastasis, and proliferation in colorectal cancer but the role of its homologue, placenta growth factor (PIGF), is unknown. The aim of this study was to evaluate expression and clinical implications of PIGF in colorectal cancer. Methods: We investigated 74 tumour/non-tumour pairs of colorectal cryosections. Clinical staging was based on the UICC-TNM classification. Expression levels of mRNA for PIGF and VEGF were analysed with quantitative real time reverse transcription-polymerase chain reaction. Proteins were analysed by immunohistochemical staining and enzyme linked immunoabsorbant assay. Analysis of the differences in PIGF and VEGF levels between tumour and non-tumour tissues in the same patient were performed by paired a' test; differences between localised and advanced disease patients by the Mann-Whitney, x² and Fisher's exact tests and survival curves by the Kaplan-Meier method. Results: Expression levels for both growth factors were significantly higher in tumour than in non-tumour tissues (p⩽ 0.001). The ratio of PIGF expression in tumour to non-tumour in the advanced disease group was significantly higher than for the localised disease group (p=0.009). Patients with more tumour PIGF mRNA had shorter survival (p = 0.028). The majority of PIGF was expressed in tumour cells. Conclusions: Our results suggest that PIGF expression correlates with disease progression and patient survival and may be used as a prognostic indicator for colorectal cancer.


Related Articles

  • Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases. Kahlert, C; Pecqueux, M; Halama, N; Dienemann, H; Muley, T; Pfannschmidt, J; Lasitschka, F; Klupp, F; Schmidt, T; Rahbari, N; Reissfelder, C; Kunz, C; Benner, A; Falk, C; Weitz, J; Koch, M // British Journal of Cancer;1/21/2014, Vol. 110 Issue 2, p441 

    Background:Tumour-associated stroma has a critical role in tumour proliferation. Our aim was to determine a specific protein expression profile of stromal angiogenic cytokines and matrix metalloproteinases (MMPs) to identify potential biomarkers or new therapy targets.Methods:Frozen tissue of...

  • Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate. Bishnuhari Paudyal; Pramila Paudyal; Shah, Dilip; Hideyuki Tominaga; Yoshito Tsushima; Keigo Endo // Journal of Biomedical Science;2014, Vol. 21 Issue 1, p1 

    Background The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with bevacizumab, and injected intravenously into nude mice bearing VEGF...

  • Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Fan, Fan; Wey, Jane S; McCarty, Marya F; Belcheva, Anna; Liu, Wenbiao; Bauer, Todd W; Somcio, Ray J; Wu, Yan; Hooper, Andrea; Hicklin, Daniel J; Ellis, Lee M // Oncogene;4/14/2005, Vol. 24 Issue 16, p2647 

    Vascular endothelial growth factor (VEGF) is associated with tumor angiogenesis and poor prognosis in human colorectal cancer (CRC). VEGF receptor-1 (VEGFR-1 or Flt-1) is a high-affinity receptor for VEGF and is typically considered specific to endothelial cells. Here we report the expression...

  • Vascular endothelial growth factor in colorectal cancer. Guba, Markus; Seeliger, Hendrik; Kleespies, Axel; Jauch, Karl-Walter; Bruns, Christiane // International Journal of Colorectal Disease;Nov2004, Vol. 19 Issue 6, p510 

    Background: Angiogenesis plays an important role in colorectal cancer progression. Evidence from preclinical and clinical studies indicates that vascular endothelial growth factor (VEGF) is the predominant angiogenic factor in human colorectal cancer and is associated with formation of...

  • Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. Naoko Yamagishi; Teshima-Kondo, Shigetada; Kiyoshi Masuda; Kensei Nishida; Yuki Kuwano; Dang, Duyen T.; Dang, Long H.; Nikawa, Takeshi; Kazuhito Rokutan // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Vascular endothelial growth factor-a (VEGF)-targeted therapies have become an important treatment for a number of human malignancies. The VEGF inhibitors are actually effective in several types of cancers, however, the benefits are transiently, and the vast majority of patients who...

  • A2B and A3 Adenosine Receptors Modulate Vascular Endothelial Growth Factor and Interleukin-8 Expression in Human Melanoma Cells Treated with Etoposide and Doxorubicin. Merighi, Stefania; Simioni, Carolina; Gessi, Stefania; Varani, Katia; Mirandola, Prisco; Tabrizi, Mojgan Aghazadeh; Baraldi, Pier Giovanni; Borea, Pier Andrea // Neoplasia;Oct2009, Vol. 11 Issue 10, p1064 

    Cancer patients undergoing treatment with systemic cancer chemotherapy drugs often have abnormal growth factor and cytokine profiles. Thus, serum levels of interleukin-8 (IL-8) are elevated in patients with malignant melanoma. In addition to IL-8, aggressive melanoma cells secrete, through its...

  • Microvessel Morphology and Vascular Endothelial Growth Factor Expression in Human Colonic Carcinoma With or Without Metastasis. Tsuji, Tsuyotoshi; Sasaki, Yoshihiro; Tanaka, Masanori; Hanabata, Norihiro; Hada, Ryukichi; Munakata, Akihiro // Laboratory Investigation (00236837);May2002, Vol. 82 Issue 5, p555 

    We quantified microvessel morphology and vascular endothelial growth factor (VEGF) expression in human colonic carcinoma with or without metastasis. The cancerous growth and the noncancerous section of surgical specimens from 36 patients with colorectal carcinoma (14 without metastasis and 22...

  • Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer. Martin, Petra; Noonan, Sinead; Mullen, Michael P.; Scaife, Caitriona; Tosetto, Miriam; Nolan, Blathnaid; Wynne, Kieran; Hyland, John; Sheahan, Kieran; Elia, Giuliano; O'Donoghue, Diarmuid; Fennelly, David; O'Sullivan, Jacintha // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can...

  • Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. Loupakis, Fotios; Cremolini, Chiara; Yang, Dongyun; Salvatore, Lisa; Zhang, Wu; Wakatsuki, Takeru; Bohanes, Pierre; Schirripa, Marta; Benhaim, Leonor; Lonardi, Sara; Antoniotti, Carlotta; Aprile, Giuseppe; Graziano, Francesco; Ruzzo, Annamaria; Lucchesi, Sara; Ronzoni, Monica; De Vita, Ferdinando; Tonini, Giuseppe; Falcone, Alfredo; Lenz, Heinz-Josef // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Purpose: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mCRC patients receiving bev-containing regimens has been investigated in retrospective experiences with contrasting results. We previously reported the association of VEGFA rs833061 C/T variants with...


Read the Article


Sign out of this library

Other Topics